Alpha-lipoic acid (ALA, thioctic acid) is one of the few supplements that is simultaneously sold in sports stores and used as a registered drug for diabetic neuropathy. Thanks to this, we have a rare advantage: clinical data on doses, tolerability and pharmacokinetics. The editors have collected practical answers to three questions - how much, when and for how long.
Where do the "correct" doses come from
Most label recommendations for ALA are based directly or indirectly on neurological studies. In the ALADIN, SYDNEY, and NATHAN series of randomized trials, thioctic acid was administered intravenously or orally to patients with diabetes and painful polyneuropathy. It was there that they most carefully studied how the dose is related to the effect and side reactions.
For people who exercise, the situation is different: convincing studies where ALA improves strength, endurance, or body composition in healthy athletes are few and small. Therefore, we consciously transfer to the sports context only what concerns safety and pharmacokinetics, and not the promise of efficacy. A dose that helps with neuropathy does not necessarily change something in the body of a healthy athlete.
The second source of data is pharmacokinetic studies on healthy volunteers. They show that ALA is quickly absorbed, reaches its peak in the blood in about half an hour to an hour, and is eliminated just as quickly: the half-life from the plasma is about 30 minutes. According to various estimates, the absolute bioavailability of the tablet racemic form is about 30%.
Finally, it is worth remembering that the body itself synthesizes lipoic acid in the mitochondria and uses it as a cofactor of enzyme complexes — pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. Endogenous lipoic acid is tightly bound to proteins, so the supplement works differently: free ALA in the blood acts as a redox couple with dihydrolipoic acid and as a signaling molecule.
How Much to Take: Ranges from Research
The key to dose selection is the SYDNEY 2 study (Ziegler et al., 2006). Patients with diabetic neuropathy received 600, 1200 or 1800 mg of ALA per day or a placebo for five weeks. Symptom improvement was similar in all active groups, but nausea, vomiting, and dizziness increased with increasing dose. The authors concluded that 600 mg per day provided the best benefit-risk ratio.
The 600 mg daily amount has been used in several neuropathy studies, including the four-year NATHAN 1 trial. That study reported more serious adverse events in the ALA group than placebo; it cannot establish universal safety. Commercial supplements often contain 100–300 mg, while some products offer 300–600 mg, but label amounts are not proof of clinical benefit.
| Context | Daily amount in studies / on labels | Editorial comment |
|---|---|---|
| General antioxidant support | 100–300 mg | Limited evidence of benefit; lower amounts do not remove all risks |
| Diabetic polyneuropathy (treatment) | 600 mg | Studied in SYDNEY 2; not a universal recommendation |
| Body weight control research | 300–1800 mg | Effect on weight is modest, higher doses are worse tolerated |
| High doses (1200–1800 mg) | Short clinical courses | Advantages over 600 mg not shown, side effects more |
The source proposed 600 mg as a ceiling and 150–300 mg as a starting amount for healthy users. These are not established safety limits or an evidence-based athletic regimen. Higher amounts more often cause digestive effects, while rare autoimmune hypoglycemia has no established risk-free intake threshold. A clinician should assess whether use has a justified purpose.
If you choose the R-form, be aware that only half of the active R-enantiomer is present in the racemic mixture. Therefore, 300 mg of R-ALA in terms of the content of the natural isomer approximately corresponds to 600 mg of the racemate, although a direct comparison of the clinical results of the two forms in large studies has not been conducted.
When to take: on an empty stomach or with food
Timing of administration is more important for ALA than for many other supplements. Pharmacokinetic studies have shown that taking with food significantly reduces the peak concentration and the total amount of the substance that enters the blood. That is why the instructions for thioctic acid medicines advise to swallow the pill on an empty stomach, about 30 minutes before breakfast.
A short plasma half-life describes the concentration profile, not the duration of every biological effect. It does not by itself prove that dividing a dose improves outcomes. Follow the prescribed formulation’s instructions rather than infer a regimen from the concentration curve.
A popular idea in the sports community is to take ALA with a carbohydrate meal to "drive glucose into the muscles." It is based on experimental data on the effect of ALA on glucose transport, but there is no practical evidence of benefits for body composition, and absorption with food is worse. If the stomach does not tolerate taking it on an empty stomach, a small snack can be a compromise.
- Some medicinal labels specify use before breakfast; follow the exact product instructions.
- If fasting administration causes discomfort, discuss tolerability and food effects with the prescriber.
- Do not increase or divide prescribed doses without discussing the indication and formulation.
Course duration and combination with training
Healthy athletes have no established evidence-based course duration. Studies discussed here range from weeks to years and involve different populations and endpoints. The source’s proposed 8–12-week reassessment is an editorial suggestion, not a validated treatment schedule; perceived benefit alone does not establish efficacy.
A separate issue is the combination of antioxidants with training. Studies with vitamin C (Gomez-Cabrera et al., 2008) and a combination of vitamins C and E (Ristow et al., 2009) have shown that high doses of antioxidants can blunt some of the adaptations to exercise, including mitochondrial biogenesis and improved insulin sensitivity. There are few direct data specifically for ALA, but the logic of caution is applicable here as well.
Findings with vitamins C and E cannot determine an effective ALA timing strategy. There is insufficient direct evidence that moving ALA away from training, or taking it in the morning, preserves adaptation or provides a favorable overall benefit–risk balance.
Breaks in intake are not mandatory from a pharmacological point of view: ALA does not accumulate in tissues and does not cause addiction. However, taking a break from time to time is useful from a practical point of view - it allows you to honestly assess whether the supplement is producing a tangible result, or whether you are taking it on the spur of the moment.
Common errors and safety monitoring
The most common mistake is to take ALA together with food and other supplements "in one handful". The second is the belief that more is better: doses of 1200–1800 mg showed no benefit even in patients with neuropathy, but more often caused nausea. The third is ignoring the interaction with hypoglycemic drugs.
ALA can lower blood glucose levels, so people taking insulin or diabetes tablets should monitor their blood sugar more often and alert their doctor. A rare but serious complication is autoimmune insulin syndrome (Hirata's disease) with episodes of severe hypoglycemia; it has been described mainly in people with a certain HLA genotype, particularly in Japan, as well as in Europeans (Gullo et al., 2014).
Because ALA is a sulfur-containing compound, some people notice a peculiar smell in their urine, which is not dangerous. Skin rash and itching rarely occur and are grounds for discontinuation. People with thiamine deficiency, in particular with alcohol abuse, should first discuss any use with a doctor.
Monitoring should reflect the indication, medical history, medicines and symptoms. A dose at or below 600 mg does not remove the possibility of adverse effects. Sweating, confusion, shaking or unexplained weakness warrant prompt assessment for hypoglycemia; severe symptoms require emergency care.
Editorial conclusions
Six hundred milligrams daily is a commonly studied clinical amount, not a universally appropriate dose or established safety ceiling for healthy athletes. Higher amounts have produced more adverse effects without greater benefit in some short trials.
Food can reduce absorption, so follow the instructions for the actual medicinal product. Pharmacokinetics alone does not establish that exact clock-time dosing improves athletic outcomes.
There is no validated supplementation course or training-timing strategy for healthy athletes. Review the clinical purpose, benefit, adverse effects and continued need with a clinician.
To complete the picture, we advise you to read our materials "Alpha-lipoic acid: formulations and which one to choose", "Who should not take Alpha-lipoic acid" and "Myths about Alpha-lipoic acid".
References
- Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370.
- Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–2060.
- Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–1160.
- Gleiter CH, Schug BS, Hermann R, et al. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol. 1996;50(6):513–514.
- Gomez-Cabrera MC, Domenech E, Romagnoli M, et al. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am J Clin Nutr. 2008;87(1):142–149.
- Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA. 2009;106(21):8665–8670.
- Gullo D, Evans JL, Sortino G, et al. Insulin autoimmune syndrome (Hirata disease) in European Caucasians taking α-lipoic acid. Clin Endocrinol (Oxf). 2014;81(2):204–209.
